A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML
Cancer Medicine · 2024
DOI: 10.1002/cam4.70401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Noor Rashidha Binte Meera Sahib und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Science Institute of Singapore, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Precision Medicine. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Science Institute of Singapore Research Centres of Excellence (RCE) Main Grant (NUS Strategic Fund), Baillie Gifford Health Innovation Fund, Singapore lYMPHoma translatiONal studY (SYMPHONY).
Abstract (Originalsprache)
Background
Despite advances made in targeted biomarker‐based therapy for acute myeloid leukemia (AML) treatment, remission is often short and followed by relapse and acquired resistance. Functional precision medicine (FPM) efforts have been shown to improve therapy selection guidance by incorporating comprehensive biological data to tailor individual treatment. However, effectively managing complex biological data, while also ensuring rapid conversion of actionable insights into clinical utility remains challenging.
Methods
We have evaluated the clinical applicability of quadratic phenotypic optimization platform (QPOP), to predict clinical response to combination therapies in AML and reveal patient‐centric insights into combination therapy sensitivities. In this prospective study, 51 primary samples from newly diagnosed (ND) or refractory/relapsed (R/R) AML patients were evaluated by QPOP following ex vivo drug testing.
Results
Individualized drug sensitivity reports were generated in 55/63 (87.3%) patient samples with a median turnaround time of 5 (4–10) days from sample collection to report generation. To evaluate clinical feasibility, QPOP‐predicted response was compared to clinical treatment outcomes and indicated concordant results with 83.3% sensitivity and 90.9% specificity and an overall 86.2% accuracy. Serial QPOP analysis in a FLT3‐mutant patient sample indicated decreased FLT3 inhibitor (FLT3i) sensitivity, which is concordant with increasing FLT3 allelic burden and drug resistance development. Forkhead box M1 (FOXM1)—AKT signaling was subsequently identified to contribute to resistance to FLT3i.
Conclusion
Overall, this study demonstrates the feasibility of applying QPOP as a functional combinatorial precision medicine platform to predict therapeutic sensitivities in AML and provides the basis for prospective clinical trials evaluating ex vivo‐guided combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Science Institute of Singapore, National University of Singapore, Singapore.
- NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
- KYAN Technologies Pte Ltd, Singapore.
- Department of Haematology, Tan Tock Seng Hospital, Singapore.
ORCID-Profile: Noor Rashidha Binte Meera Sahib, Wei-Ying Jen
Förderung
- Cancer Science Institute of Singapore Research Centres of Excellence (RCE) Main Grant (NUS Strategic Fund)
- Baillie Gifford Health Innovation Fund
- Singapore lYMPHoma translatiONal studY (SYMPHONY)
- Networks of Centres of Excellence of Canada
Zitieren
APA
Sahib, N. R. B. M., Mohamed, J. S., Rashid, M. B. M. A., Jayalakshmi, Lin, Y. C., Chee, Y. L., Fan, B. E., De Mel, S., Ooi, M. G. M., Jen, W. Y., & Chow, E. K. (2024). A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML. Cancer Medicine. https://doi.org/10.1002/cam4.70401
Vancouver
Sahib NRBM, Mohamed JS, Rashid MBMA, Jayalakshmi, Lin YC, Chee YL, et al. A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML. Cancer Medicine. 2024. doi:10.1002/cam4.70401
BibTeX
@article{Sahib2024,
author = {Sahib, Noor Rashidha Binte Meera and Mohamed, Jameelah Sheik and Rashid, Masturah Bte Mohd Abdul and Jayalakshmi and Lin, Yihao Clement and Chee, Yen Lin and Fan, Bingwen Eugene and De Mel, Sanjay and Ooi, Melissa Gaik Ming and Jen, Wei-Ying and Chow, Edward Kai-Hua},
title = {A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70401}
}
EUVIMED